Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
In the article “Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms”, published in Arq. Neuro-Psiquiatr. 2025;83(1):s00451802962, under DOI number 10.1055/s-0045-1802962 ,
Where it reads:
GENERAL RECOMMENDATIONS FOR THE PHARMACOLOGICAL TREATMENT OF PDD
Donepezil and rivastigmine are recommended to treat patients with PD-MCI or prodromal DLB.
Should be:
GENERAL RECOMMENDATIONS FOR THE PHARMACOLOGICAL TREATMENT OF PDD
Donepezil and rivastigmine are not recommended for the treatment of patients with PD-MCI or prodromal DLB.